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Societies worldwide are investing considerable resources into the safe development and use
of nanomaterials. Although each of these protective efforts is crucial for governing the risks
of nanomaterials, they are insufficient in isolation. What is missing is a more integrative gov-
ernance approach that goes beyond legislation. Development of this approach must be evi-
dence based and involve key stakeholders to ensure acceptance by end users. The challenge is
to develop a framework that coordinates the variety of actors involved in nanotechnology and
civil society to facilitate consideration of the complex issues that occur in this rapidly evolving
research and development area. Here, we propose three sets of essential elements required
to generate an effective risk governance framework for nanomaterials. (1) Advanced tools to
facilitate risk-based decision making, including an assessment of the needs of users regarding
risk assessment, mitigation, and transfer. (2) An integrated model of predicted human behav-
ior and decision making concerning nanomaterial risks. (3) Legal and other (nano-specific
and general) regulatory requirements to ensure compliance and to stimulate proactive ap-
proaches to safety. The implementation of such an approach should facilitate and motivate
good practice for the various stakeholders to allow the safe and sustainable future develop-
ment of nanotechnology.
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1. INTRODUCTION
For over a decade it has been recognized that
nanotechnologies offer great opportunities for soci-
ety, but for them to reach their full potential the
risks, particularly of nanomaterials (NMs), must be
addressed.(1) An ever-expanding heterogeneous ar-
ray of NMs are being incorporated into a diverse
range of industries and applications. This variety and
widespread use has fostered a growing interest in
their safety and risk management. Thus, key stake-
holders worldwide invest considerable resources into
the safe development and use of NMs. More specifi-
cally, governments, private companies, and other ac-
tors have sought to govern human behaviors and
decisions related to NMs through the use of vari-
ous tools and risk management efforts. For exam-
ple, internationally, much effort has been directed
to support risk assessment/management-related re-
search that will both help companies implement risk
prevention (and mitigation) strategies, as well as aid
the development of general and specific NM-relevant
regulations.(2) This work has included expert bodies
(e.g., Scientific Committee on Emerging and Newly
Identified Health Risks [SCENIHR]), regulators
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(e.g., European Food Safety Authority [EFSA], the
U.S. Food and Drug Administration (FDA) and the
U.S. Environmental Protection Agency [EPA]), as
well as academic researchers who have investigated
whether existing risk assessment procedures and
frameworks for conventional chemicals are applica-
ble to NMs. In particular, these studies and reports
have investigated and identified specific challenges
for NMs risk assessment.(3,4) This work has been
complemented by efforts aimed at fostering dialogue
with civil society and the general public in order to
explore risks and advantages (risk communication),
and with workers to facilitate a better understanding
of risks, thereby aiming to stimulate more competent
decisions and risk-reducing behavioral changes.
To align these substantial efforts, a compre-
hensive evidence-based, optimized, and transparent
risk governance framework, specifically targeted
at NMs, is now needed. Against the broad range
of governance definitions in the literature,(5) we
understand governance as the social and institutional
arrangements that systematically influence patterns
of behavior. These include formal regulations,
informal norms of appropriateness, and established
practical routines.
A coherent NM risk governance framework
should address the manifold challenges that NMs
pose to be addressed in a joined-up, coordinated
manner, thereby avoiding piecemeal solutions to NM
risk management. It would support the governance
of complex and consequential risks in the presence
of the specific challenges and uncertainty implied by
many NMs.(6)
Such a governance framework needs to be rele-
vant to risk-related behaviors and decisions by soci-
etal actors throughout the life-cycle of a given NM,
whether they are pristine materials or incorporated
into a product. It would structure decision making
and influence behaviors at the institutional and in-
dividual level, allowing identification of the options
available to the various actors while understanding
constraints such as who is entitled or required to
make a decision, who is responsible, and who is
liable.(7–9) Decisions related to NM risks are made
within a context of both hard law (formal regula-
tions and statutes) and soft law (nonbinding agree-
ments and established good practice), and nonlegal
social norms and expectations (e.g., public blaming
and shaming, reputational risks).
In this article, we address these issues by draw-
ing upon social sciences, material science, legal-
regulatory science, and risk-related research(10) to
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identify and describe essential elements of a risk gov-
ernance framework for NMs. Moreover, we provide
an outline of the tools needed for such a framework,
and how they could be integrated effectively. Finally,
we highlight the key factors required for the success
of such an integrated risk governance framework.
We believe that the proposed framework provides
a basis for a comprehensive management of NM-
related risks that will help to specify the needs for
tool development to facilitate risk decision making
and thus to foster trust in NM innovation.
2. THE NEED FOR A SPECIFIC NANO-RISK
FRAMEWORK
Currently, the legal or regulatory requirements
for nanotechnologies are spread over a fragmented
set of regulations that cover general substances (e.g.,
Registration Evaluation Authorization and Restric-
tion of Chemicals [REACH], Toxic Substances Con-
trol Act [TSCA]), specific goods containing NMs
(e.g., food law, chemical law, cosmetics law, or phar-
maceutical law), or aim to protect specific groups ex-
posed to NMs (e.g., occupational health and safety
regulation). A recent research roadmap by the Eu-
ropean NanoSafety Cluster summarizes the current
status of such regulations in Europe and the USA(11)
and includes a number of general, non-nano-specific
legal or regulatory procedures and frameworks that
are applicable to nano-relevant risks.(12–14) With re-
spect to REACH, a number of dedicated studies
(e.g., RIPON) and a REACH Review in 2012(15)
have assessed the suitability of this legislation,(16,17)
leading to a Commission Communication(18) con-
cluding that NMs “are covered by the definition of
a ‘substance’ in REACH, even though there is no ex-
plicit reference to nanomaterials.” According to the
European Commission, REACH is hence applica-
ble to NMs, making such materials subject to gen-
eral registration with ECHA. However, legally, this
interpretation is not yet binding; final clarification
would only be provided through an amendment of
REACH or a judgment by the Court of Justice of
the European Union. Likewise, the U.S. FDA re-
views risk concerns of NMs within the context of
the specific legal standards applicable to each type
of product under its jurisdiction, such as with cos-
metics, food additives, etc. This product-focused reg-
ulatory assessment empowers the FDA to conduct
pre- and postmarket reviews, and to coordinate with
established domestic and international counterparts
via the Emerging Technologies Interagency Policy
Coordination Committee.
This suggests that the governance of risks re-
lated to NMs should be considered within the context
of existing regulatory and legal frameworks. How-
ever, although the current procedures for risk as-
sessment of conventional chemicals may, in princi-
ple, be applicable to NMs,(3,4) much effort has been
made to improve this process, not only to ensure
that it is NM relevant, but also with the future am-
bition to make the process more efficient and intel-
ligent in order to deal with the ever expanding num-
ber of NMs (and nano-enabled products). Yet, cur-
rent and future NMs pose a set of specific challenges
for risk governance that may require a nano-specific
risk governance framework.(6) This demand is driven
by multiple economic and regulatory factors, includ-
ing the rapid pace of commercial or near-market de-
velopment of NMs on a global scale. A nano-specific
framework could harmonize risk-based approaches
for NM assessment for actors with traditionally di-
verging risk assessment practices, and help indicate
and ameliorate gaps in NM hazard, exposure, or ef-
fects assessment that currently drive the field’s un-
certainty with regard to health risks. Without such an
nano-specific framework, it will be difficult for regu-
lators and industry to resolve uncertainties posed by
NMs and their unique physical characteristics.
The cross-border flow of information and the in-
ternationalization of markets necessitate the devel-
opment of an international paradigm. The different
regulatory regimes, in particular different attitudes
towards the precautionary principle, suggest that a
multistakeholder approach that leverages the devel-
opment of NM best practices through the coordina-
tion of effort by industry, government, and other rel-
evant parties could be most promising in developing
shared practice that fit the various regulatory envi-
ronments.
One of the fundamental challenges for risk gov-
ernance of NMs is that NMs often share few com-
mon characteristics besides the nanoscale, and that
they can exhibit multiple forms and variations over
their life-cycles.(19) For example, NMs may undergo
changes in their physicochemical characteristics, such
as agglomeration or de-agglomeration, in certain en-
vironmental conditions, and this change may have an
impact on the toxicity of the respective NM.(6) This
challenge is further compounded by difficulties in
identifying, quantifying, and discriminating between
natural and engineered NMs.(6) Not surprisingly, this
poses problems for the characterization of properties
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Fig. 1. Essential elements for a risk governance frame-
work for nanomaterials. The central circle houses tools
that feed into a decision support system. The decisions
generated are guided by the legal/regulatory frame-
works (gray boxes), which are determined and inter-
preted by humans in real-life situations (green circle).
in toxicological studies, which may lead to diver-
sity in the applied methods and therefore difficulties
in comparing findings.(20) Consequently, any frame-
work for governing NM risks needs to pay attention
to this specific challenge and foster a viable way for
risk assessment, notably for next-generation NMs,
which efficiently considers potential changes in the
physicochemical characteristics of NMs during their
life-cycles and the likely use of incomplete data sets.
Even for a seemingly “simple” question of the
risk assessment process, NMs pose particular chal-
lenges in comparison to conventional chemicals: no
agreement so far has been reached on a concept
of dose, concentration, or metric of NMs in test
systems.(6) This renders the application of current
risk assessment practices difficult.
As well as complying with existing regulatory
and legal frameworks, any risk assessment frame-
work needs to be sufficiently flexible or adaptable
to align with new regulations as they adapt and
evolve. Examples of this include considerations of
environmental, occupational, and food/drug-based
regulatory requirements and oversight driven within
the United States by the EPA, the Occupational
Safety and Health Administration (OSHA), and
FDA, (13,21,22) or in Europe by the European
Environment Agency, EU-OSHA, or the EFSA.
Above we have addressed challenges relating
to risk-related research, material science, and the
legal-regulatory environment, but in addition, a
governance framework will benefit from integrating
perspectives from other domains, in particular
social sciences,(10) in order to develop practical
solutions for the important, urgent, and complex
risk decisions(23) regarding NMs at all societal levels.
Such a risk governance framework would signifi-
cantly contribute to the goal of achieving sustainable
development for nanotechnologies. Furthermore, it
could act as a model on which to build governance
frameworks for other key emerging technologies
(KETs). Therefore, in order to spur discussion about
such a comprehensive NM risk governance frame-
work and to suggest some key features and tools, we
proffer a tentative version of such a framework in
the following.
3. A FRAMEWORK FOR NM RISK
GOVERNANCE
3.1. The Essential Elements of the NM Risk
Governance Framework
We propose that to construct an effective risk
governance framework for NMs, three element
groups are required (see Fig. 1):
(1) A set of advanced tools and strategies to
support risk decision making. These start
with assessment of the needs of the users
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(where do they work, what experience do
they have in risk decision making, etc.) in or-
der to ensure that the information provided
is appropriate in content, style, and level of
detail.(24) This assessment of user needs will be
linked to tools for risk assessment (spanning
hazard, exposure, and physicochemical char-
acterization), mitigation (e.g., prevention of
exposure, or reduced hazard using safer-by-
design approaches), and transfer (e.g., insur-
ance), which all feed into a tool for risk deci-
sion making.(25) The tools and strategies that
address potential risks posed by NMs along
their value chain/life-cycle are currently both
experimental and computational (see Table I,
and Fig. 1, central multicolored circle). In line
with ITS-NANO,(26) we propose that the re-
liance on testing should decrease over time as
computational models become more compre-
hensive and robust.
(2) An integrated model of human behavior and
decision making (based on empirical data
gathered at the individual, organizational, na-
tional, and international level) that influences
how the framework is refined, used, and inter-
preted (Fig. 1, green circle).
(3) An integrated overview of nano-specific and
general legal-regulatory requirements, the op-
tions within which are informed by a series
of interlinked decision-making points along
the value chain and life-cycle of NMs (Fig. 1,
gray boxes). Regulations evolve with time,
and so the framework needs to be able to
adapt to changes in the broader regulatory
environment.(27) Simultaneously, by demon-
strating the need and/or ability to deal with
Table I. Definitions for Risk Management Tools
Tool Definition
Risk banding Allows risk assessment to be performed with
incomplete hazard, exposure, and
physicochemical characterization
Risk mitigation Provides advice on technical interventions
that can reduce the risk and supports
worker/decision-making training
Risk transfer Enables consideration of legal, contractual,
and insurance arrangements to be made in
the decision-making process
User needs and
capacities
Assesses expertise and experience of user to
determine the format of the information
required and the level of detail
NMs of high or unknown risk, the framework
can guide development of NM-specific regula-
tions.
We believe that the integration of these three el-
ements has the potential to generate a robust and en-
compassing risk governance framework for NMs that
fulfills the six criteria outlined below.
3.2. Criteria for a Promising NM Risk
Governance Framework
The goal of achieving sustainable development
for nanotechnologies—by instilling trust into NM
innovation and avoiding piecemeal solutions to
risk governance—forms the starting point for our risk
governance framework. Criteria for such a NM risk
governance framework therefore include:
The need to fully leverage existing knowledge
and tools. A risk governance framework is
most likely to further trust in NM inno-
vation when integrating and exploiting the
best, currently available tools (see Table I).
Projects such as caLIBRAte (European
Commission funded via Horizon 2020) are
already working towards the calibration of
such tools, and aim to collect and analyze ex-
isting control banding tools and quantitative
hazard, exposure, and risk assessment mod-
els and risk management systems for nano-
materials. Further, these tools are selected
for sensitivity analysis, performance testing,
further improvement, and calibration with a
final aim that the framework and its underly-
ing tools represent the state of the art in an-
alytical capacity to inform nanotechnology
risk governance decision making.
Robust protocols to address incomplete knowl-
edge. Risk assessment, notably for next-
generation NMs, is likely to be based on
incomplete data sets and subject to high un-
certainty. Therefore, a framework that em-
ploys effective strategies to deal with gaps in
knowledge is required.
Ability to adapt to new insights and new NMs.
Given the high velocity of developments in
the NM field, static frameworks risk falling
out of sync quickly. Therefore, a framework
must be sufficiently adaptable as to allow the
included tools to be updated for future gen-
erations of NMs, and to incorporate learning
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over time. Such an adaptive style of gover-
nance should be flexible enough to account
for the unique political and institutional re-
alities of a given jurisdiction, and allow exist-
ing regulatory structures to iteratively incor-
porate new risk knowledge over time such as
via TSCA in the United States, or REACH
regulations in the European Union.(28)
Comprehensive consideration of the motiva-
tion of various users. For a framework to
be effective, it has to accommodate the re-
sponses of the various parties (e.g., employ-
ers, workers, regulators, policymakers, in-
surers, general public) in order to motivate
compliance and best practices. Motivations
can be provided in a variety of forms, e.g.,
as financial incentives, as legal liabilities, so-
cially embedded norms of appropriateness,
role models, or via a corporate code of con-
duct.
Communicate the advantages of employing
rules and regulations. For the rules and reg-
ulations to be effective, their rationale has
to be effectively linked to the motivations,
norms, and interests of the various actors.
This requires evidence and storylines of how
they help in protecting workers, society, the
environment, and, consequently, the sustain-
ability of nano-industries.
Delivering compliance and beyond. A risk
governance framework for NMs seems most
promising in achieving the objective of sus-
tainable NMs if it not only fosters organiza-
tional practices that ensure compliance with
current and future legal and regulatory re-
quirements, but also goes beyond pure com-
pliance and stimulates proactive “good” be-
havior and innovation.
By adopting these objectives, the resultant risk
governance framework will be responsive, rational,
transparent, and inclusive in the sense that it uses and
constantly updates all available data, links them to
decision-making guidance through publicly available
rules, and integrates the needs and concerns of a wide
range of stakeholders.
3.3. Tools and Strategies for Assessing Potential
Risk and Risk Decision Making
We propose a set of four advanced tools and
strategies to support risk decision making: risk band-
ing, risk mitigation, risk transfer, and user capacities
and needs. The first tool, risk banding, stems from
risk assessment strategies. Risk assessment systemat-
ically applies scientific principles, guided by the pre-
cautionary principle, to estimate the probability that
adverse human health or environmental effects could
emerge from exposure to substances. The risk assess-
ment framework is composed of problem formula-
tion, exposure assessment, and hazard assessment, as
well as risk and uncertainty characterization.(29)
The paradigm for risk assessment of chemicals is
considered applicable to nanoscale materials,(26,30,31)
however many of the tools, test protocols, and guide-
lines for determination and assessment of physico-
chemical properties, fate, exposure, and effects used
for conventional chemicals need modifications when
applied to (the regulatory) safety assessment of NMs.
The work on adapting existing methods for NMs
has been ongoing in the Organisation for Economic
Co-operation and Development (OECD) Working
Party of Manufactured Nanomaterials (WPMN) and
in many research projects. This work has resulted
in an array of nano-specific or nano-relevant experi-
mental and modeling tools suited to address the com-
plexity associated with the identity, biological, and
environmental interactions of NMs in order to re-
duce the uncertainty in their risk assessment. These
tools were comprehensively reviewed by Hristozov
et al.(32)
These tools have been applied to generate exten-
sive physicochemical, hazard, and exposure data sets.
However, although a significant body of data exists
for some NMs, for many (including next-generation)
NMs, risk assessment is likely to be based on incom-
plete data sets. When combined with the significant
uncertainty regarding extrapolation from animal or
in vitro hazard data to the quantification of human
health or environmental risks, this lack of data could
result in an underprotective or overly conservative
assessment of health risks, resulting in either unac-
ceptable risks or stifled innovation. Given the fast de-
velopment of highly innovative NMs, it is not feasible
to complete a risk assessment of NMs on a case-by-
case basis. Hence, new approaches to risk assessment
are required(33) that allow for accelerating the risk as-
sessment process, for example, via grouping and/or
read-across of NMs.
Bodies such as the OECD and ECHA(34–36)
are developing NM grouping or categorization
schemes(37) in order to reduce the extensive hazard,
exposure, and physicochemical testing requirements
to a feasible level. A number of studies have been
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developing risk banding tools (e.g., Stoffenmanager
Nano,(38) NanoRiskCat,(39) Swiss Precautionary
Matrix, NanoSafer etc.), which are based on the
precautionary principle and are designed to in-
corporate the full range of uncertainty in their
results in order to inform risk management decisions
based on worst-case scenarios.(40) In a differing
approach, the U.S. FDA, among other agencies,
convenes quarterly interest groups that review risk
and regulatory concerns of emerging trends in NM
development, including risk categorization exercises
and product-specific regulatory discussion.(21,22)
Moreover, risk screening and ranking schemes
based on weight-of-evidence approaches have been
proposed that explicitly estimated the uncertainty
stemming from hazard and exposure assessments.
Specifically, Hristozov et al.(41) developed the first
quantitative multicriteria decision analysis (MCDA)
methodology for human health hazard identification
of NMs, which incorporated data quality evaluation
of the available data set, based on the criteria
adequacy, reliability, statistical, and toxicological
significance.(42) Moreover, a quantitative MCDA
approach for prioritization of nano-specific exposure
scenarios was proposed for occupational settings,(43)
and a quantitative MCDA methodology for human
health risk ranking of NMs was developed.(44) All
three approaches quantified the uncertainty in the as-
sessments by means of a Monte Carlo methodology.
If successful, such grouping and categorization
schemes provide the opportunity to fill missing
data within groups of similar NMs using compu-
tational (in silico) techniques such as quantitative
structure activity relationships for NMs (abbrevi-
ated as: nano-QSAR, QNAR, QNTR)(45–47) or read-
across between NMs, or between NMs and other
substances.(47) As a result, time and cost of test-
ing as well as the use of laboratory animals could
be reduced. In fact, great progress in developing
in silico methods for risk assessment of NMs has
been made by several E.U. FP7 “modeling projects”
(NanoPUZZLES, MODERN, ModENPTox, Mem-
braneNanoPart, PreNanoTox). These projects have
jointly proposed criteria important for appropriate
quality validation of nano-QSAR models to be de-
veloped in future initiatives.(48)
For such risk assessment tools to be effective,
they will require a combination of analytical, compu-
tational toxicology, machine learning, and Bayesian
methods to unravel and clearly communicate the un-
certainties in the results. The risk assessment tool
will need to provide information that is applicable to
occupational, consumer, and environmental settings,
addressing different life-cycle stages of the NMs in
order to address risks from the design and man-
ufacture stages through to disposal and recycling.
The risk assessment tool should take into account
the level of human and environmental exposure and
be sufficiently flexible to accommodate new and fu-
ture generations of NMs, even when the available
data on hazard, exposure, and physicochemical char-
acteristics are scarce or even lacking (perhaps by us-
ing expert judgment and weight-of-evidence method-
ology in a transparent manner). Any risk assessment
tool will need to push beyond the state of the art
by addressing the uncharted issues of uncertainty re-
lated to NM risks. This is relevant for consideration
of human health and environmental impact of NMs,
including susceptible group(s) in the general popu-
lation and susceptible species in the environment, as
well as the impact of NM accumulation in environ-
mental hot spots. It also includes consideration of
human behavioral uncertainties based on diverging
risk perceptions, organizational routines, and social
norms.
To allow for effective risk management of
NMs, the risk assessment tool could be linked with
tools for risk mitigation and risk transfer. A range
of practical NM risk mitigation strategies is re-
quired to reduce or prevent risks posed by NMs.
These include technical risk mitigation approaches
(e.g., safer by design), safer manufacturing pro-
cesses, safer handling procedures, and improved ex-
posure controls (e.g., high-efficiency filters). Cur-
rently, mitigation approaches, including methods and
tools, have been or are being developed in E.U.
FP7 funded projects such as SUN, SANOWORK,
NANOMICEX, NANOVALID, and GUIDEnano.
Safer-by-design approaches are also the main re-
search topics of NANoREG II and ProSAFE. Other
initiatives to prevent or minimize risk include the
development and application of the precautionary
principle, as well as soft law initiatives to drive con-
sideration of nanomaterial-derived product liabil-
ity and insurance.(49,50) Tools designed to apply the
precautionary principle are mostly inspired by the
selection of appropriate levels of engineering con-
trols (e.g., engineering techniques and personal pro-
tective equipment)(46) or green safer product design
or process optimization (e.g., NIOSH’s prevention
though design initiative).(51)
Risk mitigation strategies also include manage-
ment support tools (e.g., technical training materials
for stakeholders) designed to promote adherence to
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health and safety policies. Development of such tools
could result in improved strategic and transparent
identification of approaches to mitigate human and
environmental risks associated with NMs.
A governance framework has to provide guid-
ance for the options for a relevant selection of mit-
igation measures especially in relation to their ef-
fectiveness and the value or quality of information
about their effectiveness. Together with the defini-
tion of technical indicators (which quantify condi-
tions in which measures success or failure), this could
also facilitate the risk transfer by impacting on the
reduction of risk premiums by insurance companies.
The available options for risk transfer frame
the risk management process in relation to factors
such as noncontractual and contractual liabilities,
(re)insurability of risks, and the ensuing distribu-
tion of legal and financial risks that influence deci-
sion making. Currently, there is no systematic ap-
proach to qualify and quantify NM risk with regard
to insurance. At present, insurers implicitly assume
nano-specific risk in their health-related or general-
purpose insurance policies,(52,53) an approach they
are uncomfortable with but do not have the knowl-
edge to exclude in a competitive business. To achieve
reliable risk transfer arrangements, tools and asso-
ciated guidance are required that allow mathemati-
cal quantification of risks and risk categorization in a
context of uncertainty. In addition, tools are needed
that identify or develop legally reliable arrangements
between relevant parties involved in the life-cycle
and value chains relevant to NMs.
In order for the risk assessment, mitigation, and
transfer tools to guide effective risk management
and risk decision making, their activities and out-
puts need to be integrated. This can be achieved
through development and use of a decision support
system (DSS). Prototype risk assessment and DSSs
for NM risk management have been developed in
FP7 funded projects such as SUN and GUIDEnano.
These tools are in their early stages of development,
and are based on the exploitation of a relatively small
number of NM product case studies. Hence, a sub-
stantial body of work is required to enhance their re-
liability and suitability for wider arrays of NMs and
NM products (across their value chain/life-cycle), ex-
posure scenarios, and for a broader set of stakehold-
ers. To improve DSSs further, it will be useful in the
future to integrate the risk management tools with a
tool to assess the needs, values, and capacities of a
wide range of users. The design of such a DSS allows
the individual tools to be modified and advanced as
each is improved, thereby ensuring that it remains
up to date and relevant. Achievement of such a DSS
optimally increases the efficiency of the risk gover-
nance process, for example, by reducing the require-
ment for testing, and assists stakeholders with prac-
tical guidance in their decision-making process for
NMs throughout the value chain and life-cycle.
For the governance framework to be useful for
stakeholders, it is essential that the outputs can be
adjusted to meet the needs of the user and to provide
a level of detail that is relevant to their understand-
ing and expertise.(54) Assessment of user capacities
(e.g., experience and relevant knowledge) allows
consideration of different types and levels of exper-
tise (e.g., a “coal face” worker never involved in
risk assessment compared to an experienced occupa-
tional health professional).(55) According to this type
of analysis, the framework and tools can be adapted
to provide outputs that better suit the requirements
and understanding of different types of users.
Finally, the DSS outputs need to integrate stake-
holder values with evidence-based input in order to
recommend clear actions for decisionmakers. Prac-
tical and clear advice for regulatory compliance and
best practice should be provided. Integration of these
tools allows a national, international, and potentially
globally applicable standard for the governance of
current and future NMs and their applications to be
identified.
3.4. Human Behavior and Decision Making
Human behavior and how individuals or organi-
zations prepare and take decisions can vary consid-
erably. Variability in decision making is driven via a
wide array of factors, including the social context in
which the decision is made (e.g., domestic vs. occu-
pational settings), the perception of risks versus po-
tential benefits, the individual or organizational rou-
tines and heuristics (i.e., using decisional shortcuts
with potential for error).(56,57) These factors apply
whether the decision is made by an individual or a
team, and whether it is made to align with specific
regulations, guidelines, or ethical considerations.
To generate an effective governance framework,
there is a need to identify the individual, organiza-
tional, and societal determinants of decision mak-
ing about NM risk management and transfer along
the full value chain and life-cycle of NMs. Although
generic analytical frameworks are available to iden-
tify such determinants (e.g., the homo oeconomi-
cus institutionalis framework(58)), determinants are
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expected to vary across different types of contexts.
Hence, inputs from stakeholders and the wider pub-
lic are needed to identify how user concerns and
needs depend on the types of decisions (e.g., NM
design, which NM to use, how to dispose of a NM)
and the type of contexts (e.g., research laboratory,
factory, or in a regulatory capacity). Building on
such context-specific insights will allow for devel-
oping differentiated risk communication strategies,
which need to be dialogical (two-way) to enable co-
learning and to enhance trust in the governance of
risks from NMs.
4. IMPLEMENTATION OF THE RISK
GOVERNANCE FRAMEWORK
Before such a framework can be delivered,
the individual tools need to be generated and
validated. The tool development will need to be
evidence based, taking into account the norms and
motivations of the users and the impediments to be
addressed by the governance framework. The tools
need to be built on existing achievements of ongo-
ing or completed national or international projects,
going beyond the state of the art by systematically di-
agnosing user needs and capacities, integrating likely
behavior, dynamic links to developing knowledge
about NM risks, integration of uncertainty into risk
assessment. Importantly, to achieve this they need to
undergo interactive testing in practice.(59) Empirical
studies will therefore be required to illustrate how
the tools and guidance of the framework function
in a comprehensive and relevant range of practice
contexts, and to verify their reliability. Case studies
that do not focus on various NMs in isolation, but
rather a range of NMs along their respective value
chains and life-cycles, including interactions with
people in different settings (e.g., in industries, as
regulators, as researchers, as consumers, and in the
environment), seem a promising way to gain these
insights. Such case studies would need to include a
breadth of natural and social science data. Ideally,
each case study would demonstrate how an open
society addresses the issue of emerging technology
and its possible inherent risks in a responsible man-
ner. This will include arrangements for the transfer
of risks and the steps required by insurers before un-
derwriting any risks. It will also include signposts for
communicating the risks, in creating a narrative that
informs and involves the stakeholders in making the
key governance decisions to help nurture and sustain
the nano-industries in a socially desirable manner.
We believe that an international strategy to build
such a governance framework is necessary in order to
ensure that the framework is sufficiently adaptable
to allow and encourage improved national, interna-
tional, and global harmonization as well as sustain
and likely expand the global market for nanotech-
nology. Such a framework needs also to empower
the broad range of stakeholders in nanotechnology
governance with tools that improve practical decision
making in a governance framework that is perceived
by society as fair, trustworthy, and effective. Further-
more, it provides a vehicle to share and organize in-
formation, thereby improving the efficiency of risk
decision making.(60)
5. FUTURE STEPS
With this article, we would like to call for an
international strategy to develop an integrated risk
governance framework for NMs. This would enable
a cooperative and international approach to the
governance of NM-related risks through the system-
atic consideration and integration of stakeholder
and user needs, dynamic risk assessment tools, and
consideration of the various regulatory requirements
in multilayered and fragmented regulatory envi-
ronments. For rendering such an effort successful,
the essential elements of the framework need to be
delivered and integrated effectively. The outlined
strategy will support stakeholders with diverse back-
grounds and knowledge requirements, essentially
providing a “user paradigm” consisting of practical
advice and solutions for existing and innovative NMs
entering the market. Continued involvement of all
relevant stakeholders throughout the construction
of the framework will be essential. This inclusive
approach guarantees the maximal stakeholder
involvement through construction, consultation,
and revision phases. Furthermore, the strategy
involves the stakeholders in the design, testing, and
implementation of the framework and this process
of co-production thereby safeguards its relevance
and transparency, leading to enhanced potential for
trust.(61)
In achieving this risk governance strategy, new
solutions will be provided to evaluate the risks po-
tentially arising from the use of NMs, including fu-
ture NMs. In this regard, the governance framework
will likely have significant impact on nanotechnology
industries and for investors in nanotechnology, sup-
porting SMEs and large companies in the selection of
safer products and processes, limiting the potential
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adverse effects of NMs on workers and consumers,
and reducing insurance costs and risks to public bud-
gets derived from any potential future major acci-
dents or diseases.(62)
By enabling the emergence of reliable expecta-
tions about the behaviors and decisions along the
value chain, the governance framework proposed
here would be attractive for key stakeholders, in-
cluding the insurance industry, which underwrites the
risks of these technologies, and the financial industry,
which invests in it. It would facilitate coordinated risk
assessment, management, and communication across
diverging regulatory environments. Achievement of
such a governance framework will help to realize in-
formed, effective, responsive, and proportionate gov-
ernance of NM risks for humans and the environ-
ment. It is thus a cornerstone for optimizing social
and economic benefits of nanotechnology.
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